How We Help
NET Cancer is the FASTEST growing class of CANCER worldwide
HELP US HELP OTHERSNeuroendocrine Tumours (NETs) Overview
- Neuroendocrine tumours (NETs) are abnormal growth of cells (neoplasms) that arise from cells of the diffuse neuroendocrine system.
- NETs are considered complex tumours because both tumor growth and hormonal function must be addressed.
- NETs are most common in the lung or gastrointestinal system, but they can also originate in other parts of the body such as the thyroid, thymus, pancreas, adrenals, paraganglia, ovaries and testes.
- NETs are classified as functional (produce hormones that cause symptoms), or non-functional (may or may not produce hormones and do not cause hormonal symptoms).
- The cause of NETs is currently unknown.
Contact Us For Live Support
Support Lines:
416-628-3189
Toll Free: 1-844-628-6788
Latest CNETS Canada News
TREATMENT WITH Lutetium-177 (177Lu)-DOTATATE
REQUEST FOR PATIENT FEEDBACK ON TREATMENT WITH Lutetium-177 (177Lu)-DOTATATE (trade name Lutathera) Lutetium-177 (177Lu)-DOTATATE (trade name Lutathera), is a peptide receptor radionuclide therapy (PRRT) with radiolabeled somatostatin analogues (peptides). Lutetium-177 (177Lu)-DOTATATE treatment was approved last year [...]
PRRT Program at L’Hôtel-Dieu de Québec
Une approche novatrice contre le cancer à l'Hôtel-Dieu de Québec « Une nouvelle approche médicale attire à Québec des Canadiens, et même des Américains, atteints d'une forme rare de cancer. Le traitement offert à l'Hôtel-Dieu permet de [...]
Message from Natalie Mezey – Team Zebra Ottawa Captain
Dear Friends, This May 27th I will once again have the honour of being Team Captain for Team Zebra for Carcinoid Neuroendocrine Tumour Society (CNETS) Canada. I will be running the Half Marathon at the Ottawa Race weekend [...]
PMPRB Patient Group Consultation Submission
Patient Groups send a strong message to the Federal Minister of Health: Patient voices must be heard. We ask the @CDNMinHealth to halt the review of drug prices and move to constructive consultations. Media Release on [...]
Health Canada approves Ipsen’s Somatuline® Autogel® for the treatment of carcinoid syndrome in adult patients with neuroendocrine tumours (NETs)
Somatuline Autogel is the first and only somatostatin analog (SSA) approved in Canada to treat enteropancreatic neuroendocrine tumours and carcinoid syndrome. Februaury 13th, 2018 - Health Canada announced the approval for Somatuline® Autogel® (lanreotide injection) [...]
Raising NET Cancer Awareness on World Cancer Day
CNETS Canada Montreal Support Group Leaders Donna Hillier, Daniel Opoku and volunteer Marie-Anne Risdon set up a kiosk at the Ceders Cancer Foundation - CEDARS CANSUPPORT WORLD CANCER DAY, providing NET cancer awareness materials and [...]